IQVIA (NYSE:IQV) Given New $210.00 Price Target at Citigroup

IQVIA (NYSE:IQV) had its price objective reduced by Citigroup from $225.00 to $210.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Other equities analysts have also issued reports about the stock. Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Down 0.2 %

IQV opened at $185.45 on Tuesday. The stock has a market cap of $32.70 billion, a PE ratio of 24.73, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average of $197.95 and a 200-day moving average of $213.47. IQVIA has a 52 week low of $179.28 and a 52 week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Large investors have recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in IQVIA during the third quarter valued at approximately $27,000. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $33,000. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter worth $39,000. Finally, Lee Danner & Bass Inc. purchased a new position in IQVIA during the fourth quarter valued at $44,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.